Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is well-positioned for success with its promising product candidate, roluperidone, which has shown effectiveness and safety in Phase 2b and 3 trials. Market research indicates significant demand for treatment of negative symptoms of schizophrenia, and the company's Phase 3 trial design has been aligned with the FDA. With a strong financial standing and potential for global expansion upon positive results, Minerva is poised for future growth and success in the CNS disease treatment market.

Bears say

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development of Roluperidone, a small molecule antagonist of serotonin 5-HT2A, sigma2, and α1A-adrenergic receptors being developed to treat negative symptoms of schizophrenia. However, the company's stock has a negative outlook due to mixed results from its pivotal trials, increased competition from other biopharmaceutical companies, and the potential for a high placebo effect in its ongoing Phase 3 study. The company's potential for success is further limited by a small target market and the potential for adverse effects commonly associated with antipsychotic drugs.

Minerva Neurosciences (NERV) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Hold based on their latest research and market trends.

According to 2 analysts, Minerva Neurosciences (NERV) has a Hold consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.